腎機能検査の世界市場予測（～2028年）：タイプ別、因子別、地域別の分析

世界の腎機能検査の市場規模は、2021年に7億6,097万米ドルとなり、予測期間中に8.1％のCAGRで拡大し、2028年までに13億1,264万米ドルに達すると予測されています。

当レポートでは世界の腎機能検査市場を調査し、市場の促進要因・抑制要因、市場機会、COVID-19の影響、セグメント別の市場分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

• 促進要因
• 抑制要因
• 市場機会
• 脅威
• 製品分析
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

第5章 世界の腎機能検査市場：タイプ別

• 腎臓生検
• 希釈および濃度検査
• 画像検査
  • 計算機トモグラフィースキャン
  • 超音波
• 血液検査
  • 血中尿素窒素（BUN）検査
  • 血清クレアチニン検査
  • 糸球体濾過率（GFR）検査
• 尿検査
  • 尿検査
  • クレアチニンクリアランス検査
  • 尿タンパク検査
  • 微量アルブミン試験

第6章 世界の腎機能検査市場：因子別

• 糖尿病
• 高血圧
• 腎臓結石
• 循環器疾患
• 前立腺肥大または狼瘡
• 急性腎障害

第7章 世界の腎機能検査市場：製品別

• ディップスティック
• 使い捨て
• 機器
• キットとアッセイ
• 試薬
• ソフトウェア

第8章 世界の腎機能検査市場：疾患別

• 慢性
• 急性

第9章 世界の腎機能検査市場：エンドユーザー別

• 病院と診療所
• 外来手術センター
• 診断検査室
• 調査・研究機関

第10章 世界の腎機能検査市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東・アフリカ

第11章 主な発展

• 契約、パートナーシップ、コラボレーション、ジョイントベンチャー
• 買収と合併
• 新製品の発売
• 拡張
• その他の重要な戦略

第12章 企業プロファイル

• Abbott
• Acon Laboratories
• Arkray
• Baxter International Inc
• Cook Medical
• Danaher Corporation (Beckman Coulter, Inc)
• F. Hoffmann-La Roche
• Laboratory Corporation of America Holdings (LabCorp)
• Nova Biomedical
• Opti Medical
• Quest Diagnostics
• Randox Laboratories
• Siemens Healthineers
• Sysmex
• Urit Medical
• Bio-Techne Corporation
• Eurofins Viracor
• Horizon Therapeutics plc

List of Tables

• Table 1 Global Kidney Function Tests Market Outlook, By Region (2020-2028) (US $MN)
• Table 2 Global Kidney Function Tests Market Outlook, By Type (2020-2028) (US $MN)
• Table 3 Global Kidney Function Tests Market Outlook, By Kidney Biopsy (2020-2028) (US $MN)
• Table 4 Global Kidney Function Tests Market Outlook, By Dilution and Concentration Tests (2020-2028) (US $MN)
• Table 5 Global Kidney Function Tests Market Outlook, By Imaging Tests (2020-2028) (US $MN)
• Table 6 Global Kidney Function Tests Market Outlook, By Computed Tomography Scan (2020-2028) (US $MN)
• Table 7 Global Kidney Function Tests Market Outlook, By Ultrasound (2020-2028) (US $MN)
• Table 8 Global Kidney Function Tests Market Outlook, By Blood Tests (2020-2028) (US $MN)
• Table 9 Global Kidney Function Tests Market Outlook, By Blood Urea Nitrogen (BUN) Tests (2020-2028) (US $MN)
• Table 10 Global Kidney Function Tests Market Outlook, By Serum Creatinine Tests (2020-2028) (US $MN)
• Table 11 Global Kidney Function Tests Market Outlook, By Glomerular Filtration Rate (GFR) Tests (2020-2028) (US $MN)
• Table 12 Global Kidney Function Tests Market Outlook, By Urine Tests (2020-2028) (US $MN)
• Table 13 Global Kidney Function Tests Market Outlook, By Urinalysis (2020-2028) (US $MN)
• Table 14 Global Kidney Function Tests Market Outlook, By Creatinine Clearance Tests (2020-2028) (US $MN)
• Table 15 Global Kidney Function Tests Market Outlook, By Urine Protein Tests (2020-2028) (US $MN)
• Table 16 Global Kidney Function Tests Market Outlook, By Microalbumin Tests (2020-2028) (US $MN)

Table17 Global Kidney Function Tests Market Outlook, By Factor (2020-2028) (US $MN)

• Table 18 Global Kidney Function Tests Market Outlook, By Diabetes (2020-2028) (US $MN)
• Table 19 Global Kidney Function Tests Market Outlook, By High Blood Pressure (2020-2028) (US $MN)
• Table 20 Global Kidney Function Tests Market Outlook, By Kidney Stones (2020-2028) (US $MN)
• Table 21 Global Kidney Function Tests Market Outlook, By Cardiovascular Disease (2020-2028) (US $MN)
• Table 22 Global Kidney Function Tests Market Outlook, By Enlarged Prostate or Lupus (2020-2028) (US $MN)
• Table 23 Global Kidney Function Tests Market Outlook, By Acute Kidney Injury (2020-2028) (US $MN)
• Table 24 Global Kidney Function Tests Market Outlook, By Product (2020-2028) (US $MN)
• Table 25 Global Kidney Function Tests Market Outlook, By Dipsticks (2020-2028) (US $MN)
• Table 26 Global Kidney Function Tests Market Outlook, By Disposables (2020-2028) (US $MN)
• Table 27 Global Kidney Function Tests Market Outlook, By Instruments (2020-2028) (US $MN)
• Table 28 Global Kidney Function Tests Market Outlook, By Kits and Assay (2020-2028) (US $MN)
• Table 29 Global Kidney Function Tests Market Outlook, By Reagents (2020-2028) (US $MN)
• Table 30 Global Kidney Function Tests Market Outlook, By Software (2020-2028) (US $MN)
• Table 31 Global Kidney Function Tests Market Outlook, By Disease (2020-2028) (US $MN)
• Table 32 Global Kidney Function Tests Market Outlook, By Chronic (2020-2028) (US $MN)
• Table 33 Global Kidney Function Tests Market Outlook, By Acute (2020-2028) (US $MN)
• Table 34 Global Kidney Function Tests Market Outlook, By End User (2020-2028) (US $MN)
• Table 35 Global Kidney Function Tests Market Outlook, By Hospitals & Clinics (2020-2028) (US $MN)
• Table 36 Global Kidney Function Tests Market Outlook, By Ambulatory Surgical Centers (2020-2028) (US $MN)
• Table 37 Global Kidney Function Tests Market Outlook, By Diagnostic Laboratories (2020-2028) (US $MN)
• Table 38 Global Kidney Function Tests Market Outlook, By Research Laboratories and Institutes (2020-2028) (US $MN)

Note- Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

According to Stratistics MRC, the Global Kidney Function Tests Market is accounted for $760.97 million in 2021 and is expected to reach $1312.64 million by 2028 growing at a CAGR of 8.1% during the forecast period. Kidney function tests are procedures that usually use either the blood or urine to help identify issues in the kidneys. These tests are performed to check if the kidneys are filtering waste products too slowly and to see if the kidneys are leaking proteins into the urine. Regular kidney function tests help to identify issues in the early stages, making it possible to halt the progress of the disease.

Market Dynamics:

Driver:

Increasing expansions in diagnostic testing methods for early diagnosis of renal disorders

Due to growing developments in diagnostic testing methods for the initial diagnosis of renal disorders or diseases affecting kidney function are driving revenue growth in the market. For example, when compared to current practice using laboratory blood tests, point-of-care (POC) creatinine testing for the identification and monitoring of chronic kidney disease delivers enhanced accuracy and value in the monitoring and early identification of CKD. Rapid creatinine level results from such PoC testing deliver immediate input and information to the patient. This type of testing delivers real-time kidney function updates, which are essential for dose adjustments owing to renal impairment. They also offer rapid and accurate home testing, which allows for continuous monitoring, early diagnosis, and management of the deteriorated renal function. These factors are anticipated to drive revenue growth in the market.

Restraint:

Stringent government regulations

The stringent government guidelines leading to the use of specific methods in kidney tests may restrain the market revenue growth. The kidney is a very important organ of the human body and to examine any Chronic Kidney Disease (CKD) in an individual, a kidney test function is needed. Therefore, the function test has to follow many strict government regulations and also undergo strict regulations for approval. For instance, if a patient has a CKD and needs to undergo a kidney transplant, the patient, as well as the hospitals, needs to follow proper documentation or bonds under the laws of the government, which might be challenging.

Opportunity:

Emergent Market

Public-private organizations are working to make kidney disease diagnostics more reachable in key areas. Diabetic patients are tested for kidney damage regularly according to the new guidelines. These activities are anticipated to generate a favourable environment for market expansion. An increase in the incidence and prevalence of chronic kidney disease across the world is a creating opportunity for the growth market.

Threat:

Low precision of prediction models based on kidney function tests and overuse of kidney function tests

The Cockcroft-Gault [C-G] and Modification of Diet in Renal Disease [MDRD] equations are two key expectation equations for adults based on serum creatinine readings from kidney function tests. These prediction equations based on kidney function tests are found to be incorrect in the case of patients with normal and near-normal kidney function, which may lead to misdiagnosis and inaccurate assessment of renal function in patients. Moreover, overuse of tests delivers little value to patients and increases the cost strain on healthcare systems. These factors are predicted to threaten market revenue growth.

Urine Tests segment is expected to be the largest during the forecast period

The urine tests segment is anticipated to expand at a rapid pace during the forecast period which can be accredited to the ease in sample collection and very low risk of infection. The increasing use of urine dipstick analysis, the convenience of sample collection compared to blood tests that can cause discomfort and swelling, and the shallow risk of infection owing to sample collection can all be related to the significant share of the urine test segment's rapid growth rate.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment held the largest market share. This high share is accredited to growing hospital visits owing to the rising awareness about CKD and its treatment. Besides, the development of sophisticated infrastructures across numerous provinces, which help in performing efficient diagnostic procedures, will contribute to the segment's share. Moreover, the growing number of awareness campaigns about kidney function tests and the growing focus of emerging economies on increasing the number of hospitals.

Region with highest share:

The Asia Pacific is projected to hold the highest market share, owing to the fast-developing healthcare facilities and rise in investments by leading market players. Besides, the existence of a large target population in emerging countries, such as China and India, is expected to drive the regional market during the forecast period. Additionally, an increase in the number of high blood pressure and diabetes patients, who develop chronic kidney diseases, a rise in health awareness, and a surge in demand for advanced diagnostic and therapeutic regimens for chronic kidney diseases in the province are motivating the market growth.

Region with highest CAGR:

North America is projected to have the highest CAGR, owing to well-established healthcare infrastructure, high awareness levels about CKD, and favourable reimbursement policies & government initiatives. Moreover, the local presence of major market players and the easy availability of technologically advanced products. Additionally, high prevalence of the disease, especially in the U.S., and high affordability and awareness levels of the people in this province.

Key players in the market:

Some of the key players profiled in the Kidney Function Tests Market include Abbott, Acon Laboratories, Arkray, Baxter International Inc, Cook Medical, Danaher Corporation (Beckman Coulter, Inc), F. Hoffmann-La Roche, Laboratory Corporation of America Holdings (LabCorp), Nova Biomedical, Opti Medical, Quest Diagnostics, Randox Laboratories, Siemens Healthineers, Sysmex, Urit Medical, Bio-Techne Corporation, Eurofins Viracor, Horizon Therapeutics plc.

Key developments:

In Apr-2020: Nova Biomedical announced the addition of PT/INR testing to its Allegro capillary blood analyzer for point-of-care testing in primary care settings. This update enables the company to supervise patient coagulation therapy along with the testing for glycemic control, anaemia, kidney function, gout, and cardiac risk with a full lipids panel..

In March 2021: Bio-Techne Corporation announced that it published positive preliminary data on its kidney transplant rejection test, ExoTRU (Exosome Transplant Rejection Urine) stating that it is capable of discriminating between types of kidney rejection, providing critical information to assist clinician decision making and optimizing patient care.

In March 2020: Horizon Therapeutics plc announced the launch of "Down and Out Kidney", a campaign to highlight the damaging effects associated with the accumulation of uric acid and gout in people with chronic kidney disease (CKD).

In Jul-2019: LabCorp expanded its Pixel by LabCorp platform. This latest offering enables users to buy testing online, visit a convenient LabCorp patient service centre (PSC) for sample collection by a LabCorp phlebotomist, and get confidential results via a safe online portal.

Types Covered:

• Kidney Biopsy
• Dilution and Concentration Tests
• Imaging Tests
• Blood Tests
• Urine Tests

Factors Covered:

• Diabetes
• High Blood Pressure
• Kidney Stones
• Cardiovascular Disease
• Enlarged Prostate or Lupus
• Acute Kidney Injury

Products Covered:

• Dipsticks
• Disposables
• Instruments
• Kits and Assay
• Reagents
• Software

Diseases Covered:

• Chronic
• Acute

End Users Covered:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Research Laboratories and Institutes

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025 and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Kidney Function Tests Market, By Type

• 5.1 Introduction
• 5.2 Kidney Biopsy
• 5.3 Dilution and Concentration Tests
• 5.4 Imaging Tests
  • 5.4.1 Computed Tomography Scan
  • 5.4.2 Ultrasound
• 5.5 Blood Tests
  • 5.5.1 Blood Urea Nitrogen (BUN) Tests
  • 5.5.2 Serum Creatinine Tests
  • 5.5.3 Glomerular Filtration Rate (GFR) Tests
• 5.6 Urine Tests
  • 5.6.1 Urinalysis
  • 5.6.2 Creatinine Clearance Tests
  • 5.6.3 Urine Protein Tests
  • 5.6.4 Microalbumin Tests

6 Global Kidney Function Tests Market, By Factor

• 6.1 Introduction
• 6.2 Diabetes
• 6.3 High Blood Pressure
• 6.4 Kidney Stones
• 6.5 Cardiovascular Disease
• 6.6 Enlarged Prostate or Lupus
• 6.7 Acute Kidney Injury

7 Global Kidney Function Tests Market, By Product

• 7.1 Introduction
• 7.2 Dipsticks
• 7.3 Disposables
• 7.4 Instruments
• 7.5 Kits and Assay
• 7.6 Reagents
• 7.7 Software

8 Global Kidney Function Tests Market, By Disease

• 8.1 Introduction
• 8.2 Chronic
• 8.3 Acute

9 Global Kidney Function Tests Market, By End User

• 9.1 Introduction
• 9.2 Hospitals & Clinics
• 9.3 Ambulatory Surgical Centers
• 9.4 Diagnostic Laboratories
• 9.5 Research Laboratories and Institutes

10 Global Kidney Function Tests Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Abbott
• 12.2 Acon Laboratories
• 12.3 Arkray
• 12.4 Baxter International Inc
• 12.5 Cook Medical
• 12.6 Danaher Corporation (Beckman Coulter, Inc)
• 12.7 F. Hoffmann-La Roche
• 12.8 Laboratory Corporation of America Holdings (LabCorp)
• 12.9 Nova Biomedical
• 12.10 Opti Medical
• 12.11 Quest Diagnostics
• 12.12 Randox Laboratories
• 12.13 Siemens Healthineers
• 12.14 Sysmex
• 12.15 Urit Medical
• 12.16 Bio-Techne Corporation
• 12.17 Eurofins Viracor
• 12.18 Horizon Therapeutics plc